- Dec 14, 2018 -
Sitagliptin,an inhibitor of type 2 diabetes, was developed by Merck and sold in the United States on October 17, 2006. Is a new hypoglycemic drug, can improve the ability of the human body to reduce the level of hyperglycemia. By inhibiting the activity of the enzyme, the levels of naturally occurring intestinal insulin, including glucagon like peptide-1 and glucose-dependent insulin-stimulating peptide, are relatively increased, which triggers the pancreas to increase insulin production and to stop glucose production in the liver. Clinical effect of reducing blood glucose concentration.
The synthesis of Stagliptin involves many intermediates. one of our main selling product ,Meldrum's acid is the intermedicate of Sagliptin.We produce Meldrum's acid 300MT per year. The quality is very guaranteed. Our markets are mainly India and Japan